Please login to the form below

Not currently logged in
Email:
Password:

FDA warning for BMS’ leukaemia drug

The US Food and Drug Administration has updated the label of Bristol-Myers Squibb's leukaemia drug Sprycel with a warning that the drug can increase the risk of abnormally high blood pressure in the arteries of the lungs

The US Food and Drug Administration (FDA) has updated the label of Bristol-Myers Squibb's (BMS) leukaemia drug Sprycel (dasatinib) with a warning that the drug can increase the risk of abnormally high blood pressure in the arteries of the lungs.

The condition, known as pulmonary arterial hypertension (PAH) is a potentially serious disorder that can weaken the heart and cause shortness of breath, fatigue, and swelling of the body.

The FDA made the updates to Sprycel's label based on data contained in BMS' global pharmacovigilance database that some patients developed PAH after starting Sprycel, including after more than one year of treatment.

Sprycel was initially approved in the US in June 2006. No fatalities from the condition have been reported, according to the FDA.

The regulatory agency also stated that patients diagnosed with PAH during Sprycel therapy were often taking other medications at the same time, and there may be a combination of factors contributing to the development of PAH in patients taking Sprycel.

Healthcare professionals are advised to evaluate patients for signs and symptoms of underlying cardiopulmonary disease prior to starting Sprycel and also during treatment. If PAH is confirmed, Sprycel should be permanently discontinued.

12th October 2011

Share

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
PRMA Consulting Ltd

PRMA Consulting is an independent consultancy solving some of the most challenging pricing, reimbursement and market access issues facing international...

Latest intelligence

Report: Achieving launch excellence in the challenging healthcare markets of today
Our in-depth report is based on original data and expert interviews, which coupled with our own experience, ensures we give you the best recommendations for achieving launch success in challenging...
What is blockchain and why should i care - Richard Springham
Four Health - Emerging Technologies The power of blockchain lies in the fact it can prove that a unique event occurred at a certain time with out the need to...
NHS medicines optimisation milestone
Steve How, Paul Midgley and Oli Hudson, of the Wilmington Healthcare Consulting Team, explore the implications of Adalimumab’s recent European patent expiry...

Infographics